Huachuang Securities: maintains a "buy" rating on Jin Xin Reproduction (01951.HK) with a target price of 3.23 Hong Kong dollars.

According to the Zhixin Finance APP, Huachuang Securities released a research report stating that domestic assisted reproduction has been fully included in medical insurance, combined with support policies such as fertility subsidies, and the industry penetration rate is expected to accelerate. As a leading company in the industry, Jinxin Reproductive (01951.HK) has significant advantages in brand and licenses, and short-term business disruptions do not change the long-term growth trend. The bank predicts that the company's revenue for the years 2025-2027 will be 26.02, 28.67, and 31.78 billion yuan respectively; the adjusted net profit attributable to mothers is forecasted to be 2.82, 3.25, and 3.76 billion yuan. The bank has set a target stock price of 3.23 Hong Kong dollars and maintains a "recommended" rating.